KRAS and colorectal cancer: On the other hand, it has been shown that inhibition of autophagy sensitizes KRAS-mutant colorectal cancer cells to concurrent use of glycolysis and mevalonate pathway inhibitors [196], suggesting that multiple metabolisms may be targeted simultaneously.